Sobi updates outlook after Alprolix wins CHMP backing

Swedish rare disease specialist Swedish Orphan Biovitrum (STO: SOBI) has upgraded its financial outlook for 2016 after receiving positive feedback on hemophilia B drug Alprolix (coagulation Factor IX [Recombinant], Fc fusion protein).

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has backed Alprolix for marketing authorization and Sobi anticipates the European Commission will grant it later this year.

As a result, the company now expects total revenues for the full year to be in the range of 4,800 million to 5,000 million Swedish kroner ($556.36 million to $579.54 million).